Cargando…
Drug-resistant tuberculosis: an experience from Qatar
This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC),...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170354/ https://www.ncbi.nlm.nih.gov/pubmed/32238120 http://dx.doi.org/10.1080/19932820.2020.1744351 |
_version_ | 1783523876397907968 |
---|---|
author | Ali, Maisa Howady, Faraj Munir, Waqar Karim, Hanfa Al-Suwaidi, Zubaida Al-Maslamani, Muna Alkhal, Abdullatif Elmaki, Nada Ziglam, Hisham |
author_facet | Ali, Maisa Howady, Faraj Munir, Waqar Karim, Hanfa Al-Suwaidi, Zubaida Al-Maslamani, Muna Alkhal, Abdullatif Elmaki, Nada Ziglam, Hisham |
author_sort | Ali, Maisa |
collection | PubMed |
description | This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010 – March 2015. Demographic, clinical data, drug-resistance pattern of isolated mycobacteria and treatment outcome was assessed for the patient who completed their treatment in Qatar. Of 3301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to at least one drug. The overall prevalence of multi-d rug resistant TB (MDR-TB) was 1.2% (n = 38) of patients. A former resident of Indian sub contents was the most common demographic characteristic observed (64.1%). The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment. Cure and relapse rates were 97.6%, and 2.4%, respectively. Drug-resistant TB in Qatar is influenced by migration where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug-susceptibility testing should be the standard of care. |
format | Online Article Text |
id | pubmed-7170354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-71703542020-04-27 Drug-resistant tuberculosis: an experience from Qatar Ali, Maisa Howady, Faraj Munir, Waqar Karim, Hanfa Al-Suwaidi, Zubaida Al-Maslamani, Muna Alkhal, Abdullatif Elmaki, Nada Ziglam, Hisham Libyan J Med Research Article This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010 – March 2015. Demographic, clinical data, drug-resistance pattern of isolated mycobacteria and treatment outcome was assessed for the patient who completed their treatment in Qatar. Of 3301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to at least one drug. The overall prevalence of multi-d rug resistant TB (MDR-TB) was 1.2% (n = 38) of patients. A former resident of Indian sub contents was the most common demographic characteristic observed (64.1%). The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment. Cure and relapse rates were 97.6%, and 2.4%, respectively. Drug-resistant TB in Qatar is influenced by migration where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug-susceptibility testing should be the standard of care. Taylor & Francis 2020-04-02 /pmc/articles/PMC7170354/ /pubmed/32238120 http://dx.doi.org/10.1080/19932820.2020.1744351 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ali, Maisa Howady, Faraj Munir, Waqar Karim, Hanfa Al-Suwaidi, Zubaida Al-Maslamani, Muna Alkhal, Abdullatif Elmaki, Nada Ziglam, Hisham Drug-resistant tuberculosis: an experience from Qatar |
title | Drug-resistant tuberculosis: an experience from Qatar |
title_full | Drug-resistant tuberculosis: an experience from Qatar |
title_fullStr | Drug-resistant tuberculosis: an experience from Qatar |
title_full_unstemmed | Drug-resistant tuberculosis: an experience from Qatar |
title_short | Drug-resistant tuberculosis: an experience from Qatar |
title_sort | drug-resistant tuberculosis: an experience from qatar |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170354/ https://www.ncbi.nlm.nih.gov/pubmed/32238120 http://dx.doi.org/10.1080/19932820.2020.1744351 |
work_keys_str_mv | AT alimaisa drugresistanttuberculosisanexperiencefromqatar AT howadyfaraj drugresistanttuberculosisanexperiencefromqatar AT munirwaqar drugresistanttuberculosisanexperiencefromqatar AT karimhanfa drugresistanttuberculosisanexperiencefromqatar AT alsuwaidizubaida drugresistanttuberculosisanexperiencefromqatar AT almaslamanimuna drugresistanttuberculosisanexperiencefromqatar AT alkhalabdullatif drugresistanttuberculosisanexperiencefromqatar AT elmakinada drugresistanttuberculosisanexperiencefromqatar AT ziglamhisham drugresistanttuberculosisanexperiencefromqatar |